Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV8BI4)

Drug Name

MK-6325 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hepatitis C virus Serine protease NS4A (HCV NS4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TG-2349	DMZ571Y	Hepatitis C virus infection	1E51.1	Phase 2	[3]
PHX-1766	DMERJ6V	Hepatitis C virus infection	1E51.1	Phase 1	[4]
IDX-320	DMAYLS3	Hepatitis C virus infection	1E51.1	Discontinued in Phase 1/2	[5]
GS-9132	DMXB4T9	Hepatitis C virus infection	1E51.1	Discontinued in Phase 1/2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis C virus Serine protease NS4A (HCV NS4A)	TTRHUKY	POLG_HCV1	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01329913) Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003). U.S. National Institutes of Health.
2	Synthesis of bis-macrocyclic HCV protease inhibitor MK-6325 via intramolecular sp -sp Suzuki-Miyaura coupling and ring closing metathesis. Org Lett. 2015 Mar 20;17(6):1533-6.
3	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4	Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design. Antivir Ther. 2012;17(2):365-75.
5	Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.Antivir Ther.2012;17(4):633-42.